Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

BACKGROUND: Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable when darunavir 800 mg once daily was co-administered with cobicistat 150 mg once daily (as single agents or a fixed-dose combination) vs. with ritonavir 100 mg once daily....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:AIDS Res Ther
Päätekijät: Tashima, Karen, Crofoot, Gordon, Tomaka, Frank L, Kakuda, Thomas N, Brochot, Anne, Van de Casteele, Tom, Opsomer, Magda, Garner, William, Margot, Nicolas, Custodio, Joseph M, Fordyce, Marshall W, Szwarcberg, Javier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413526/
https://ncbi.nlm.nih.gov/pubmed/25926858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-11-39
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia